211 related articles for article (PubMed ID: 22283750)
1. The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
Egerton A; Stone JM
Curr Pharm Biotechnol; 2012 Jun; 13(8):1500-12. PubMed ID: 22283750
[TBL] [Abstract][Full Text] [Related]
2. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
Stone JM
Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
[TBL] [Abstract][Full Text] [Related]
3. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
5. Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development.
Egerton A; Grace AA; Stone J; Bossong MG; Sand M; McGuire P
Schizophr Res; 2020 Sep; 223():59-70. PubMed ID: 33071070
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
Sonnenschein SF; Grace A
Expert Opin Ther Targets; 2021 Jan; 25(1):15-26. PubMed ID: 33170748
[No Abstract] [Full Text] [Related]
7. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
Gaspar PA; Bustamante ML; Silva H; Aboitiz F
J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Müller N
Curr Opin Investig Drugs; 2010 Jan; 11(1):31-42. PubMed ID: 20047157
[TBL] [Abstract][Full Text] [Related]
9. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
Coyle JT; Basu A; Benneyworth M; Balu D; Konopaske G
Handb Exp Pharmacol; 2012; (213):267-95. PubMed ID: 23027419
[TBL] [Abstract][Full Text] [Related]
10. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
Kolomeets NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
[TBL] [Abstract][Full Text] [Related]
11. The association between
Beck K; Arumuham A; Brugger S; McCutcheon RA; Veronese M; Santangelo B; McGinnity CJ; Dunn J; Kaar S; Singh N; Pillinger T; Borgan F; Sementa T; Neji R; Jauhar S; Aigbirhio F; Boros I; Turkheimer F; Hammers A; Lythgoe D; Stone J; Howes OD
J Psychopharmacol; 2022 Sep; 36(9):1051-1060. PubMed ID: 36120998
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiologically based treatment interventions in schizophrenia.
Lewis DA; Gonzalez-Burgos G
Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
[TBL] [Abstract][Full Text] [Related]
13. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
14. Functional neuroimaging in schizophrenia: diagnosis and drug discovery.
McGuire P; Howes OD; Stone J; Fusar-Poli P
Trends Pharmacol Sci; 2008 Feb; 29(2):91-8. PubMed ID: 18187211
[TBL] [Abstract][Full Text] [Related]
15. Imaging the glutamatergic system in vivo--relevance to schizophrenia.
Bressan RA; Pilowsky LS
Eur J Nucl Med; 2000 Nov; 27(11):1723-31. PubMed ID: 11105831
[TBL] [Abstract][Full Text] [Related]
16. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
[TBL] [Abstract][Full Text] [Related]
18. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.
Moghaddam B; Javitt D
Neuropsychopharmacology; 2012 Jan; 37(1):4-15. PubMed ID: 21956446
[TBL] [Abstract][Full Text] [Related]
19. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
20. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK
JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
